[COVID-19 in the intensive care unit].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Becker AP; Mang S; Rixecker T; Lepper PM
  • Source:
    Pneumologie (Stuttgart, Germany) [Pneumologie] 2024 May; Vol. 78 (5), pp. 330-345. Date of Electronic Publication: 2024 May 17.
  • Publication Type:
    Journal Article; Review; English Abstract
  • Language:
    German
  • Additional Information
    • Transliterated Title:
      Intensivmedizinische Therapie von COVID-19.
    • Source:
      Publisher: Thieme Country of Publication: Germany NLM ID: 8906641 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1438-8790 (Electronic) Linking ISSN: 09348387 NLM ISO Abbreviation: Pneumologie Subsets: MEDLINE
    • Publication Information:
      Original Publication: Stuttgart ; New York : Thieme, [c1989-
    • Subject Terms:
      COVID-19*/prevention & control ; COVID-19*/therapy ; Intensive Care Units* ; Respiratory Distress Syndrome*/therapy ; Respiratory Distress Syndrome*/etiology ; Critical Care*/methods; Humans
    • Abstract:
      The acute respiratory failure as well as ARDS (acute respiratory distress syndrome) have challenged clinicians since the initial description over 50 years ago. Various causes can lead to ARDS and therapeutic approaches for ARDS/ARF are limited to the support or replacement of organ functions and the prevention of therapy-induced consequences. In recent years, triggered by the SARS-CoV-2 pathogen, numerous cases of acute lung failure (C-ARDS) have emerged. The pathophysiological processes of classical ARDS and C-ARDS are essentially similar. In their final stages of inflammation, both lead to a disruption of the blood-air barrier. Treatment strategies for C-ARDS, like classical ARDS, focus on supporting or replacing organ functions and preventing consequential damage. This article summarizes the treatment strategies in the intensive care unit.
      Competing Interests: Erklärung zu finanziellen Interessen Forschungsförderung erhalten: nein; Honorar/geldwerten Vorteil für Referententätigkeit erhalten: ja, von einem/den Sponsor(en) dieser Fortbildungseinheit; Bezahlter Berater/interner Schulungsreferent/Gehaltsempfänger: nein; Patent/Geschäftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an im Bereich der Medizin aktiven Firma: nein; Patent/Geschäftsanteile/Aktien (Autor/Partner, Ehepartner, Kinder) an zu Sponsoren dieser Fortbildung bzw. durch die Fortbildung in ihren Geschäftsinteressen berührten Firma: nein Erklärung zu nichtfinanziellen Interessen Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
      (Thieme. All rights reserved.)
    • Publication Date:
      Date Created: 20240517 Date Completed: 20240517 Latest Revision: 20240517
    • Publication Date:
      20240518
    • Accession Number:
      10.1055/a-1854-2693
    • Accession Number:
      38759701